

David Madigan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2276602/publications.pdf>

Version: 2024-02-01

41
papers

2,974
citations

257450

24
h-index

302126

39
g-index

43
all docs

43
docs citations

43
times ranked

3990
citing authors

#	ARTICLE	IF	CITATIONS
1	Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. <i>Studies in Health Technology and Informatics</i> , 2015, 216, 574-8.	0.3	533
2	Characterizing treatment pathways at scale using the OHDSI network. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 7329-7336.	7.1	256
3	Good practices for real-world data studies of treatment and/or comparative effectiveness: Recommendations from the joint ISPOR-SPE Special Task Force on real-world evidence in health care decision making. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1033-1039.	1.9	251
4	Good Practices for Real-World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR-SPE Special Task Force on Real-World Evidence in Health Care Decision Making. <i>Value in Health</i> , 2017, 20, 1003-1008.	0.3	243
5	Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. <i>Lancet</i> , 2019, 394, 1816-1826.	13.7	228
6	Empirical assessment of methods for risk identification in healthcare data: results from the experiments of the Observational Medical Outcomes Partnership. <i>Statistics in Medicine</i> , 2012, 31, 4401-4415.	1.6	154
7	Evaluating the Impact of Database Heterogeneity on Observational Study Results. <i>American Journal of Epidemiology</i> , 2013, 178, 645-651.	3.4	149
8	Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model. <i>ACM Transactions on Modeling and Computer Simulation</i> , 2013, 23, 1-17.	0.8	113
9	Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. <i>JAMA Internal Medicine</i> , 2020, 180, 542.	5.1	97
10	Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2571-2577.	7.1	91
11	Association Between Trauma Center Type and Mortality Among Injured Adolescent Patients. <i>JAMA Pediatrics</i> , 2016, 170, 780.	6.2	76
12	Pooled Analysis of Rofecoxib Placebo-Controlled Clinical Trial Data. <i>Archives of Internal Medicine</i> , 2009, 169, 1976.	3.8	74
13	A Comparison of the Empirical Performance of Methods for a Risk Identification System. <i>Drug Safety</i> , 2013, 36, 143-158.	3.2	71
14	Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. <i>Hypertension</i> , 2021, 78, 591-603.	2.7	63
15	Empirical Performance of a New User Cohort Method: Lessons for Developing a Risk Identification and Analysis System. <i>Drug Safety</i> , 2013, 36, 59-72.	3.2	57
16	Large-scale regression-based pattern discovery: The example of screening the WHO global drug safety database. <i>Statistical Analysis and Data Mining</i> , 2010, 3, 197-208.	2.8	53
17	Improving reproducibility by using high-throughput observational studies with empirical calibration. <i>Philosophical Transactions Series A, Mathematical, Physical, and Engineering Sciences</i> , 2018, 376, 20170356.	3.4	53
18	Robust empirical calibration of p -values using observational data. <i>Statistics in Medicine</i> , 2016, 35, 3883-3888.	1.6	43

#	ARTICLE	IF	CITATIONS
19	Multiple Self-Controlled Case Series for Large-Scale Longitudinal Observational Databases. <i>Biometrics</i> , 2013, 69, 893-902.	1.4	35
20	How Confident Are We About Observational Findings in Health Care: A Benchmark Study. , 2020, 2, .		32
21	Sequential event prediction. <i>Machine Learning</i> , 2013, 93, 357-380.	5.4	31
22	Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1331-1337.	4.4	31
23	Empirical Performance of the Caseâ€“Control Method: Lessons for Developing a Risk Identification and Analysis System. <i>Drug Safety</i> , 2013, 36, 73-82.	3.2	28
24	Does design matter? Systematic evaluation of the impact of analytical choices on effect estimates in observational studies. <i>Therapeutic Advances in Drug Safety</i> , 2013, 4, 53-62.	2.4	27
25	Commentary: What Can We Really Learn From Observational Studies?. <i>Epidemiology</i> , 2011, 22, 629-631.	2.7	26
26	Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. <i>Scientific Reports</i> , 2020, 10, 11115.	3.3	23
27	Under-reporting of cardiovascular events in the rofecoxib Alzheimer disease studies. <i>American Heart Journal</i> , 2012, 164, 186-193.	2.7	22
28	Comprehensive Comparative Effectiveness and Safety of First-Line β -Blocker Monotherapy in Hypertensive Patients. <i>Hypertension</i> , 2021, 77, 1528-1538.	2.7	20
29	Large-scale evidence generation and evaluation across a network of databases (LEGEND): assessing validity using hypertension as a case study. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 1268-1277.	4.4	19
30	Persistence of Cardiovascular Risk After Rofecoxib Discontinuation. <i>Archives of Internal Medicine</i> , 2010, 170, 2035.	3.8	13
31	Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx. <i>Psychometrika</i> , 2017, 82, 459-474.	2.1	13
32	Hierarchical models for multiple, rare outcomes using massive observational healthcare databases. <i>Statistical Analysis and Data Mining</i> , 2016, 9, 260-268.	2.8	11
33	Streamlining cardiovascular clinical trials to improve efficiency and generalisability. <i>Heart</i> , 2017, 103, 1156-1162.	2.9	10
34	Learning From Epidemiology: Interpreting Observational Database Studies for the Effects of Medical Products. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 170-179.	0.8	7
35	Predicting health outcomes from highâ€“dimensional longitudinal health histories using relational random forests. <i>Statistical Analysis and Data Mining</i> , 2015, 8, 128-136.	2.8	7
36	Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database. <i>Open Access Journal of Contraception</i> , 2018, Volume 9, 29-32.	1.4	6

#	ARTICLE	IF	CITATIONS
37	Bayesian hierarchical vector autoregressive models for patient-level predictive modeling. PLoS ONE, 2018, 13, e0208082.	2.5	5
38	DUPLICATE: Recommendations for Good Procedural Practices for Real-World Data Studies of Treatment Effectiveness and/or Comparative Effectiveness Designed to Inform Health Care Decisions: Report of the Joint ISPOR-ISPE Special Task Force on Real-World Evidence in Health Care Decision Making. Value in Health, 2017, , .	0.3	1
39	Response to Marsh, G. M., Ierardi, A. M., Benson, S. M., & Finley, B. L. (2019). Occupational exposures to cosmetic talc and risk of mesothelioma: an updated pooled cohort and statistical power analysis with consideration of latency period. Inhalation toxicology, 31(6), 213â€“223. Inhalation Toxicology, 2019, 31, 385-386.	1.6	1
40	Reassessing mechanism as a predictor of pediatric injury mortality. Journal of Surgical Research, 2015, 199, 641-646.	1.6	0
41	2402. Journal of Clinical and Translational Science, 2017, 1, 76-77.	0.6	0